Roche builds CLL case for Gazyva in two-horse race with GSK

Emily Wasserman

won FDA approval for a supplemental license application of its chronic lymphocytic leukemia drug , strengthening its over rival GlaxoSmithKline and adding some ammo to its hemo-oncology arsenal.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS